Core Viewpoint - WuXi Biologics (02269) anticipates a revenue growth of approximately 16.7% for the fiscal year 2025, reaching RMB 21.79 billion, driven by successful execution of its "follow and win molecule" strategy and advanced technology platforms [1] Financial Performance - The gross profit margin is expected to increase by about 5 percentage points to 46% [1] - Adjusted gross profit is projected to grow by 25.5% year-on-year to approximately RMB 10.638 billion [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5.733 billion [1] - Net profit is forecasted to increase by about 46.3% to RMB 4.908 billion [1] - Adjusted net profit is anticipated to grow by around 22% to RMB 6.586 billion [1] Growth Drivers - Revenue growth is attributed to the successful execution of the "follow and win molecule" strategy, leading technology platforms, industry-best project delivery times, and excellent project execution track record [1] - Increased revenue from advanced technology research services and utilization of existing and new production capacities, including ramp-up at European production facilities [1] - Cost savings and efficiency improvements achieved through lean operational management systems and digital solutions, along with investment income from the portfolio [1]
药明生物盈喜后高开逾3% 预期2025年净利润49.08亿元 同比增长46.3%